^
    Back
    Association details:
    Biomarker:Chr del(11)(q22.3)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

    Published date:
    07/26/2021
    Excerpt:
    Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib...After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms...
    DOI:
    10.1200/JCO.21.01210
    Trial ID:
    ELEVATE-RR
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood
    Title:

    Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

    Published date:
    04/09/2020
    Excerpt:
    In this phase 1b/2 study, 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median prior therapies, 2 [range, 1-13]) received acalabrutinib...responses were similar regardless of genomic features (presence of del(11)(q22.3), del(17)(p13.1), complex karyotype, or immunoglobulin variable region heavy chain mutation status).
    DOI:
    10.1182/blood.2018884940
    Trial ID:
    ACE-CL-001